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CD10−/ALDH− cells are the sole cisplatin-resistant
component of a novel ovarian cancer stem cell
hierarchy
Brendan Ffrench1,2, Claudia Gasch1,2,9, Karsten Hokamp3, Cathy Spillane1,2, Gordon Blackshields2, Thamir Mahmoud Mahgoub1,2,
Mark Bates4, Louise Kehoe1, Aoibhinn Mooney5, Ronan Doyle1,2, Brendan Doyle1,2, Dearbhaile O’Donnell6, Noreen Gleeson4,
Bryan T Hennessy7, Britta Stordal8, Ciaran O’Riain1, Helen Lambkin5, Sharon O’Toole4, John J O’Leary1,2 and Michael F Gallagher*,1,2

It is long established that tumour-initiating cancer stem cells (CSCs) possess chemoresistant properties. However, little is known of
the mechanisms involved, particularly with respect to the organisation of CSCs as stem-progenitor-differentiated cell hierarchies.
Here we aimed to elucidate the relationship between CSC hierarchies and chemoresistance in an ovarian cancer model. Using a single
cell-based approach to CSC discovery and validation, we report a novel, four-component CSC hierarchy based around the markers
cluster of differentiation 10 (CD10) and aldehyde dehydrogenase (ALDH). In a change to our understanding of CSC biology, resistance
to chemotherapy drug cisplatin was found to be the sole property of CD10−/ALDH− CSCs, while all four CSC types were sensitive to
chemotherapy drug paclitaxel. Cisplatin treatment quickly altered the hierarchy, resulting in a three-component hierarchy dominated
by the cisplatin-resistant CD10−/ALDH− CSC. This organisation was found to be hard-wired in a long-term cisplatin-adapted model,
where again CD10−/ALDH− CSCs were the sole cisplatin-resistant component, and all CSC types remained paclitaxel-sensitive.
Molecular analysis indicated that cisplatin resistance is associated with inherent- and adaptive-specific drug efflux and DNA-damage
repair mechanisms. Clinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples. Collectively,
these data advance our understanding of the relationship between CSC hierarchies and chemoresistance, which was shown to be
CSC- and drug-type specific, and facilitated by specific and synergistic inherent and adaptive mechanisms. Furthermore, our data
indicate that primary stage targeting of CD10−/ALDH− CSCs in specific ovarian cancer patients in future may facilitate targeting of
recurrent disease, before it ever develops.
Cell Death and Disease (2017) 8, e3128; doi:10.1038/cddis.2017.379; published online 19 October 2017

Tumour-initiating cells within the heterogeneous tumour are
referred to as ‘cancer stem cells’ (CSCs) owing to their stem
cell-like properties of self-renewal, differentiation and (malignant) tissue genesis.1–3 Many studies have shown that CSCs
from different malignancies are chemoresistant.4 CSCs are
potential clinical targets, particularly for the treatment of
refractory disease, but CSC targeting has not been efficiently
translated to the clinic.1,5 This may be due to the complex
organisation of CSCs as stem-progenitor-differentiated cell
hierarchies. Current models indicate that, in vivo, a highly
plastic, immature CSC sits at the apex of a unidirectional tree
structure. The apex CSC produces more mature, less plastic
CSCs, which are referred to as (committed) ‘progenitors’,
which produce mature, specialised (‘differentiated’) cells,
which form the bulk of the tumour.2 Contemporary CSC theory
indicates that the developing tumour is a collection of
hierarchically arranged apex CSCs, progenitor CSCs and
differentiated cells. However, the degree to which different
CSC types contribute to chemoresistance is unknown.

Platinum-based chemotherapy, a cornerstone of cancer
treatment, targets DNA by generating intrastrand and interstrand crosslinks (ICLs), triggering apoptosis at the G1/S
phase cell cycle checkpoint.6 Cisplatin resistance is associated with two mechanisms. First, multi-drug resistance
(MDR) genes, which have a strong association with chemoresistant cells, facilitate active efflux of chemotherapy drugs out
of the cell. The best characterised of these is the ATP-binding
cassette (ABC) transporter family.7 Second, DNA-damage
response (DDR) mechanisms facilitate efficient repair of ICLs
via the Fanconi anaemia (FA) pathway.8–10 Briefly, the FA core
complex (FANCA/B/C/E/F/G/L/M) recognises and binds the
ICL and recruits and activates the key FANCD2–FANCI
heterodimer, which facilitates unhooking of the ICL. Subsequently, BRCA2 (breast cancer, early onset 2)-driven homologous recombination, sometimes referred to as the FA/BRCA
pathway, regenerates targeted DNA, facilitating continuation
through the cell cycle and a resumption of proliferation.
Importantly, FA/BRCA pathway DDR is regulated by several
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Figure 1 Identification of a novel ALDH ovCSC. The cisplatin-sensitive, treatment-naive cancer model A2780 and its cisplatin-adapted counterpart A2780cis were screened
for the presence of putative CSC populations based on the expression of CD44, CD113, CD117 and CXCR4, as well as Hoechst efflux capacity (Side Population assay) and
ALDH activity (Supplementary Data 1). Both cell types contained a population with strong ALDH activity (a): A2780, (b): A2780cis, flow cytometry using ALDH inhibitor DEAB as a
negative control. ALDH+ and ALDH− cells were isolated from the A2780 model by FACS and found to efficiently generate xenograft tumours in vivo (c), n = 4 for each cell type that
were confirmed as representative of ovarian cancer by pathological analysis (H+E staining, (d): ALDH+, (e): ALDH−). Cells of each type were plated singly, allowed to develop into
colonies and then assessed for the presence of ALDH+ and ALDH− cells (SCAD assay). (f) SCAD assays demonstrated that ALDH+ cells could produce ALDH+ and ALDH− cell
types, validating them as CSCs, n = 4. (g) Some ALDH− clones (termed ALDH− A, n = 4) were found to generate both cell types, validating them as CSCs also. (h) However,
other ALDH − clones (termed ALDH− B, n = 6) were found to produce only ALDH − cells. When isolated by FACS, ALDH− B cells were also found to efficiently generate xenograft
tumours in vivo (c). Similar results were generated for the A2780cis model (Supplementary Data 1).These data indicated the presence of a complex CSC network, the elucidation
of which required identification of a second marker, a process that is described in Supplementary Data 2. All experiments were conducted in three biological replicates and
statistical significance was determined as described in Materials and Methods section
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Figure 2 CD10+/ALDH+ is the apex component of a novel ovCSC network. CD10 was identified as an ALDH− A marker as described in Supplementary Data 2, resulting in
identification of four putative CSC populations via flow cytometry (CD10+/ALDH+, CD10 −/ALDH−, CD10+/ALDH−, CD10−/ALDH+: a, centre). Each of the four populations was
similarly capable (no significant (NS) difference in latency period, first sight of tumour growth, time from injection to end point or percentage of mice generating tumours) of
generating xenograft tumours from as little as 90 cells, validating them as true CSCs (b; Population mean comparison using analysis of variance test. Data shown are mean ± S.
D. of n ⩾ 3 mice). Histological analysis demonstrated an ovarian cancer-like pathology (c: CD10−/ALDH−, d: CD10+/ALDH−, e: CD10−/ALDH+, f: CD10+/ALDH+), with no
consistent differences between the populations. All four populations were plated as single cells and assessed for their relationship to one another via SCAD assay (a). (g) This
analysis was summarised and modelled and identified CD10+/ALDH+ as the most potent, apex CSC. Unusually, this apex CSC could be produced by less potent CD10−/ALDH+
CSCs. The two additional low-potency CSCs were capable of producing one another. Rather than the standard hierarchical, tree structure, this novel CD10/ALDH model is
apparently a CSC Network
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ubiquitination/de-ubiquitination steps, which form part of the
ubiquitin proteasome system (UPS).11 In contrast, taxane
chemotherapeutics target microtubule stability, which leads to
apoptosis at G2/M of the cell cycle. As cells do not have a

Cell Death and Disease

microtubule repair system, taxane resistance is associated
with mechanisms such as tubulin isotype mutations that affect
taxane–microtubule binding.12 It is likely that identification and
targeting of specific chemoresistance mechanisms in specific
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CSC types could enhance treatment of refractory disease.
In this study, single-cell analysis facilitated generation and
validation of a novel four-component CSC hierarchy from a
cisplatin-sensitive, treatment-naive ovarian cancer model
based around the expression of the stem cell markers cluster
of differentiation 10 (CD10) and aldehyde dehydrogenase
(ALDH). Despite the dogma that all CSCs are broadly
chemoresistant, all four CSC subtypes were found to be
paclitaxel sensitive, while cisplatin resistance was the property
of only CD10−/ALDH− CSCs. The CSC hierarchy adapted to
short- and long-term cisplatin treatment, which was associated with specific expression of MDR and DDR mechanisms.
Together, these data indicate, for the first time, that CSC
chemoresistance is not universal and can be CSC-type and
drug-type specific, which suggests important, novel considerations for clinical targeting strategies.
Results
CD10+/ALDH+ CSCs are the apex population in a new,
four-component, cisplatin-sensitive, treatment-naive
ovarian CSC network. The study began with the identification of the CD10 and ALDH markers through a screening and
validation process (described in detail in Supplementary Data
1) in both the cisplatin-sensitive treatment-naive cancer
model A2780 (Figure 1) and its long-term cisplatin-adapted
counterpart A2780cis. A2780/A2780cis is a highly characterised cisplatin-sensitive/-adapted model that was originally
derived from a treatment-naive ovarian cancer patient
of unknown histology/pathology. Four populations were
identified within the A2780 cell line: CD10+/ALDH−
(60.33 ± 0.21%), CD10−/ALDH− (39.41 ± 0.21%), CD10+/ALDH+
(0.2 ± 0.01%), and CD10−/ALDH+ (0.06 ± 0.01%) (Figure 2a,
Supplementary Data 1). Each population was isolated by
FACS, validated as a true CSC via generation of a xenograft
tumour from o100 cells (Figures 2b–f), and assessed for
their relationships to one another via single-cell asymmetric
division (SCAD: described in detail in Supplementary Data 1)
assay (Figure 2a). This data indicated the presence of a
novel, four-component ovarian CSC (ovCSC) network, with a
small CD10+/ALDH+ population as the most potent, apex
CSCs (Figure 2g). This hierarchy is not a common tree
structure and is non-linear: progenitor CSCs (CD10−/ALDH−
and CD10−/ALDH+) can produce one another, and one,
CD10+/ALDH−, can produce the apex CSC. It is further noted

that all four populations showed at least one clone that did not
display asymmetric division in the SCAD assay (Figure 2a),
suggesting the presence of additional rare, non-CSC
populations.
CD10−/ALDH− CSCs are the only cisplatin-resistant
component of the CD10/ALDH hierarchy. The CSC network was next assessed for cisplatin sensitivity. A2780 cells
were exposed to their 48 h cisplatin IC50 (Figure 3a) for 72 or
96 h, and the effect on each hierarchy component was
assessed by flow cytometry. At 72 h, only the CD10−/ALDH−
population displayed cisplatin resistance, while the other
three subpopulations showed substantial cell death relative to
untreated and vehicle-treated controls (Figures 3d–f). By 96 h
the CD10+/ALDH+ apex CSC population was undetectable,
while the CD10−/ALDH− population increased from
38.66 ± 3.18% (treatment naive) to 98.35 ± 0.97% post
cisplatin-treatment (Figures 3e and f). Although the CD10+
/ALDH+ and CD10−/ALDH+ populations were too small to
facilitate toxicology analysis, it was subsequently shown that
the CD10−/ALDH− population had a cisplatin IC50 of
9.6 ± 0.6 μM compared with only 4.1 ± 0.2 μM for the A2780
parent cell line (Figure 3c). Finally, an identical experiment
was performed for paclitaxel treatment (Figures 3b and g–i).
Although there was substantial cell death during the assay
(Figure 3g), the flow cytometric profile for the network was
unaffected (Figures 3h and i), indicating that all populations
were equally paclitaxel sensitive.
CD10−/ALDH− CSCs are the dominant population of a
three-component cisplatin-adapted ovCSC hierarchy.
The A2780cis parent cell line has been cisplatin adapted by
long-term exposure to increasing doses of cisplatin, which, it
is recommended, should be added to the cells every 2–3
passages. A2780cis parent cells were grown in the absence
of cisplatin to avoid passage to passage alterations to the
hierarchy induced by addition of the drug. As described in
detail in the next section, this had no effect on cisplatin
tolerance in A2780cis cells. In line with the data observed for
96 h cisplatin-treated A2780 cells (Figures 3d and f),
A2780cis parent cells were found to contain only three
CD10/ALDH populations, CD10+/ALDH+ CSCs being undetectable (Figure 4a). All CSC populations were again
validated by successful generation of tumours from o100
cells in xenograft assays (Figures 4b–g). Although some

Figure 3 CD10−/ALDH− CSCs are the chemoresistant component of the CD10/ALDH ovCSC network. Dose–response analysis was used to calculate IC50s of (a)
4.1 ± 0.2 μM for cisplatin, n = 3; and (b) 4.6 ± 1.0 nM for paclitaxel, n = 3 for A2780 cells. To elucidate the relationship between the CD10/ALDH network and chemoresistance,
A2780 cells were treated with cisplatin for (d and e) 72 and (f) 96 h, and the effect on the four populations was then assessed via flow cytometry (e and f). Although untreated and
DMSO vehicle-treated control cells were unaffected (d–f), cisplatin treatment resulted in a substantial cell death (d). Flow cytometry indicated that this was due to substantial cell
death in the CD10+/ALDH+, CD10−/ALDH+ and CD10+/ALDH− populations (e and f). In contrast, a proportional increase in the size of the CD10−/ALDH− population was
observed (e and f). This was confirmed by statistical analysis (bar charts, unpaired Student’s t-test, mean population size (%) ± S.D. of n = 3, NS = not significant, ***Pvalueo0.0001). Notably, by 96 h (d and f) the apex CD10+/ALDH+ CSC has been depleted to the point of being undetectable. Although the CD10+/ALDH+ and CD10−/ALDH+
populations were too small to facilitate toxicology assays, cisplatin dose–response curves (c: IC50, left panel; statistical analysis, right panel) showed that the CD10−/ALDH−
CSCs (IC50 = 9.6 ± 0.6 μM; n = 3) were proportionally cisplatin resistant and the CD10+/ALDH− CSCs proportionally cisplatin sensitive (IC50 = 4.2 ± 0.3 μM; n = 3). In contrast,
A2780 cells were found to have a much lower tolerance for paclitaxel (b: IC50 = 4.6 ± 1.0 nM). (h) Seventy-two and (i) 96 h 4.6 nM paclitaxel treatment was found to result in
substantial cell death (g), which affected all four populations uniformly. Together, these data indicate that CD10−/ALDH− CSCs are the sole cisplatin-resistant component of this
ovCSC network. As these cells had not been exposed to cisplatin previously, this is deemed to be inherent chemoresistance. However, these data indicate that the entire ovCSC
network is highly sensitive to paclitaxel
Cell Death and Disease
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Figure 4 Cisplatin adaptation hard-wires changes to the CD10/ALDH ovCSC network. (a) Flow cytometric analysis indicated that the A2780cis model contained only three
CD10/ALDH populations, as CD10+/ALDH+ cells were undetectable. This suggests that the altered flow cytometric profile observed when the A2780 model was treated with
cisplatin for 96 h has been hard-wired in the A2780cis model. (b) All three populations could generate xenograft tumours from as little as 90 cells, validating them as true CSCs.
Some differences were observed between CD10−/ALDH− and CD10−/ALDH+ CSCs (first sight of tumour growth, time from injection to end point, b, *P-valueo0.05). There was
no significant (NS) difference in latency period. (c) Additionally, it was noted that tumour formation and colony formation was slower in A2780cis CSCs compared with A2780
CSCs. A2780cis populations were found to more efficiently form colonies than A2780 populations (60 ± 4% on average compared with 23 ± 14%, respectively). (d) In addition,
A2780cis populations were found to grow tumours significantly slower than A2780 populations. Histological analysis demonstrated an ovarian cancer-like pathology. (e): CD10−/
ALDH−, (f): CD10−/ALDH+, (g): CD10+/ALDH−), with no consistent differences between the populations. (h) All three populations were plated as single cells and assessed for
their relationship to one another via SCAD assay. (i) This analysis was summarised and modelled and indicated the absence of an obvious (potency-based) apex CSC in this
network. Instead, it appears that both CD10−/ALDH+ and CD10+/ALDH− CSCs are now focussed on production of the cisplatin-resistant CD10−/ALDH− component. (Population
mean comparison using analysis of variance test. Data shown are mean ± S.D. of n ⩾ 3 mice. Flow cytometric statistics presented as bar charts, NS = not significant,
*P-valueo0.05; ** P-valueo0.01, ***P-valueo0.001)
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Figure 5 CD10−/ALDH− CSCs display adaptive cisplatin resistance and paclitaxel sensitivity. To further elucidate the relationship between the CD10/ALDH network and
chemoresistance, (a) cisplatin and (b) paclitaxel IC50s were established. A2780cis cells were found to be more resistant to cisplatin than A2780 cells (a: A2780cis
IC50 = 11 ± 0.4 μM; n = 3). A cisplatin dose–response curve indicated that this appears to be due to acquired cisplatin resistance of CD10−/ALDH− CSCs (b:
IC50 = 20.1 ± 0.4 μM; n = 3). In contrast, A2780 and A2780cis cells were found to be similarly sensitive to paclitaxel (c: A2780cis IC50 = 5.2 ± 0.2 μM). A2780cis cells were
treated with cisplatin for 72 (e and f) and 96 (e and g) hours. Although untreated and DMSO vehicle-treated control cells were unaffected, cisplatin treatment resulted in a
proportional increase in the CD10−/ALDH− population, as the other populations showed substantial cell death (d–g). (h–i) Seventy-two and (h and j) 96 h 4.6 nM paclitaxel
treatment resulted in substantial cell death (h), which affected all three populations uniformly (h–j). All data were confirmed by statistical analysis (bar charts, unpaired Student’s ttest, mean population size (%) ± S.D. of n = 3, NS = not significant, ***P-valueo0.0001). Together, these data indicate that CD10−/ALDH− CSCs possess inherent and acquired
cisplatin-resistance mechanisms. Again, the entire ovCSC network is highly sensitive to paclitaxel
Cell Death and Disease
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differences were observed between CD10−/ALDH− and
CD10−/ALDH+ populations (first sight of tumour growth, time
from injection to endpoint), there was no significant difference
in latency period (Figure 4b). Notably, xenograft formation
was significantly slower in A2780cis populations compared
with A2780 populations (Figure 4d). Additionally, A2780cis
cells were found to form colonies significantly slower than
A2780 cells, despite A2780cis cells being more efficient at
forming colonies (Figure 4c). On average, it took a single
A2780cis cell 5–6.5 weeks to grow into colonies of 5 × 106
cells. In contrast, single-plated A2780 cells took 4–4.5 weeks
to form colonies containing similar cell numbers. SCAD
assays demonstrated an altered hierarchy relationship, with
no obvious (potency-based) apex CSC (Figures 4h and i).
Specifically, the entire cis-hierarchy is now focussed upon
self-renewal and production of the CD10−/ALDH− cisplatinresistant population. As such, it appears that the effects of
96 h cisplatin treatment of A2780 cells are hard-wired,
perhaps by longer-term exposure, even when cisplatin is
withdrawn for several months.
A2780cis CD10−/ALDH− CSCs display adaptive cisplatin
resistance. As described above, the A2780cis parent cell
line was cultured in the absence of cisplatin for several
months to avoid inconsistent growing conditions. Subsequently, A2780cis cells were found to have retained cisplatin
tolerance (IC50 = 11 ± 0.4 μM, Figure 5a), in line with our
previous description.13 This indicates that prolonged exposure to cisplatin results in a hard-wired tolerance that is no
longer cisplatin dependent. Interestingly, A2780cis parent
cells were found to remain highly sensitive to paclitaxel
(Figure 5c).
Parent A2780cis cells were treated with their 48 h 11 μm
cisplatin IC50 (Figures 5d–g), continuing this treatment for 72
and 96 h, and the relative effect on the three CSC populations
was assessed by flow cytometry (Figures 5f and g). The
results demonstrated that there is substantial cell death
following cisplatin treatment (Figures 5d and e). Flow
cytometric analysis demonstrated that cisplatin treatment
diminished the cisCD10+/ALDH− and cisCD10−/ALDH+ populations relative to untreated and vehicle-treated controls, while
the cisCD10−/ALDH− population increased in size
(Figures 5d–g). This adaptive cisplatin resistance was

confirmed by dose–response analysis to be the specific
property of cisCD10−/ALDH− CSCs (Figure 5b). In isolation,
cisCD10−/ALDH− CSCs were found to be more cisplatin
tolerant than A2780cis parent cells, which is suggestive of
proapoptotic paracrine signalling by the other populations
(Figure 5b). This is evidence for a continued dominant role for
the CD10−/ALDH− CSC population, which can further develop
inherent cisplatin tolerance through adaptation. Treatment of
A2780cis parent cells with their paclitaxel IC50 (Figure 5c)
resulted in substantial cell death at 72 and 96 h (Figures 5h–j),
which affected all three CSC populations uniformly (Figures 5i
and j). As such, while it appears that the inherent cisplatinresistance mechanism seen in CD10−/ALDH− CSCs is hardwired in cisCD10−/ALDH− CSCs, the latter population displays additional adaptive cisplatin-resistance mechanisms.
The demonstration that all CSC populations are highly
sensitive to paclitaxel may have important clinical implications.
Specific enhanced MDR and DDR mechanisms are
associated with inherent and adaptive CD10−/ALDH−
cisplatin resistance. The molecular mechanisms associated with inherent and adaptive cisplatin resistance of
CD10−/ALDH− CSCs were characterised using wholegenome gene expression arrays. The complete set of
analysis is described in Supplementary data 3 and summarised in Figure 6 and Table 1. Comparison of (A) CD10−/
ALDH− CSCs with the A2780 parent cell line and (B)
cisCD10−/ALDH− CSCs with the A2780cis parent cell line
established respective genelists of 1772 (inherent;
Supplementary Data 4) and 919 (adapted; Supplementary
Data 6) differentially expressed genes. Analysis of these
genelists via the online bioinformatics resource DAVID
highlighted several cisplatin-resistance-related mechanisms
(Inherent: Supplementary Data 5; Adaptive: Supplementary
Data 7), which are summarised in Figure 6c. In summary,
cisplatin resistance is characterised by inherent-specific,
adaptive-specific and common expression of MDR and
DDR genes, as illustrated in Figure 6c. Specifically, the data
suggest a mechanism where (A) cisplatin is effluxed from the
cell to reduce ICL formation, (B) ICLs are recognised and
processed by specific components of the FA and UPS
pathways, (C) time for repair is facilitated through G1/S and
G2/M cell cycle checkpoints and antiapoptosis mechanisms

Figure 6 Inherent and adaptive cisplatin resistance in CD10−/ALDH− CSCs is associated with enhanced MDR and DDR mechanisms. The molecular mechanisms
associated with CD10−/ALDH− CSC inherent and adaptive cisplatin resistance were identified using whole-genome gene expression array analysis. (a and b) Biological
replicates of each cell type were found to cluster well. The full genelists and molecular relationships identified by the online tool ‘DAVID’ are shown in Supplementary Data 4.
Selected molecular relationships for inherent and adaptive cisplatin resistance are detailed in Table 1. The majority of these genes relate to specific, inherent- and adaptiveresistance MDR and DDR mechanisms. As illustrated ((c): inherent genes in green, adaptive genes in red, common genes in black font), these relate to drug efflux (MDR), UPS,
the FA pathway (DDR), cell cycle checkpoints, antiapoptosis, and homologous recombination. These data indicate a mechanism where cisplatin resistance of CD10−/ALDH−
CSCs is facilitated by an enhanced ability to efflux and repair cisplatin-induced ICLs, which is further enhanced by prolonged drug exposure(d–k). To assess its clinical relevance,
CD10/ALDH expression was assessed using the online resource tool Kaplan–Meier Plotter (kmplot.com), which facilitates filtered analysis across a large number of published
studies. In each case, the numbers of patients within the cohort who had high or low expression of the protein is shown in red and black, respectively. Statistical significance is
indicated as logrank P (cutoff Po0.05) as well as relative risk of progressive disease (PFS curves) or death (OS curves) as hazard ratio (HR: cutoff o0.77 or 41.3). For each
set of analyses, data are shown for p53wt samples only (‘p53wt’) or all p53 types (‘all p53’). This analysis indicated that CD10 negativity was a predictor of poor PFS (d–e,
P = 0.00049, HR = 0.36), with a trend towards worse OS (f–g, P = 0.056, HR = 0.55), but only in cases of serous carcinoma patients with p53wt disease. Low expression of
ALDH1A3 was also found to be a predictor of reduced PFS (h, P = 0.021, HR = 0.51) but not OS in p53 wildtype (j, P = 0.062, HR = 1.8) or in either PFS (i, P = 0.0092,
HR = 1.22) or OS (j, P = 0.0033, HR = 1.23) when all p53 types were considered together. As a further validation, CD10 expression was assessed in a TMA (Supplementary
Data 8) containing germinal centres of (l) tonsil positive control and (m) ovarian cancer patient tumour samples prepared by our group. CD10 expression was negative in the
epithelium of all tumour samples (m). In conclusion, CD10/ALDH negativity/low expression may have some utility as prognostic indicators but further validation is required
Cell Death and Disease
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Figure 6 (Continued)

and (D) return to proliferation is facilitated following BRCA2driven homologous recombination (Figure 6c). We note the
expression of an inherent-resistance mechanism (Figure 6c,
green text) by cells that have never experienced cisplatin
treatment. Notably, adaptive resistance (Figure 6c, red text) is
associated with specific expression of genes associated with
Cell Death and Disease

the FA pathway, particularly the key genes FANCB and
FANCI, and further upregulation of BRCA2. In parallel, while
the cell cycle checkpoint mechanism is lost in adaptive
cisplatin resistance, an antiapoptotic mechanism is suggested by downregulation of proapototic genes. We propose
that these increases in the FA pathway and BRCA2 indicate
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Table 1 Selected genes specifically expressed by CD10−/ALDH− CSCs, as identified by DAVID analysis (Full list in Supplementary Data 4-7)

Genes

P-value

ATAD5, BLM, FANCL, GEN1, RAD54B, RIF1, SMG1, SP100, SLK, ATRX, BRCA2, ESCO1,
EYA4, MNAT1, MAPK26, PARP4, POLK, POLQ, RFC1, RFC3, RBBP8, SETX, SMC3, SMC5,
SMC6, TOBP1, USP1, UBE2N, UACA
BLM, FANCL, GEN1, RAD54B, SMG1, SLK, ATRX, BRCA2, ESCO1, EYA4, MNAT1, PARP4,
POLK, POLQ, RFC1, RFC3, RBBP8, SETX, SMC3, SMC5, SMC6, TOBP1, USP1, UBE2N
BLM, NIPBL, PDS5A, PDS5B, RAD54B, REC8, SKP2, TARDBP, TTK, BRCA2, CENPE,
CENPF, SKA3, CUL5, ITGB1, KIF15, KIF18A, KIF20B, MNAT1, NPAT, PIM1, PBRM1, RB1,
RBBP8, SMC2, SMC3, SMC4, TDRD1
BLM, TTK, CENPE, CENPF, DLG1, RB1, RBBP8, TPR

2.7 × 10 − 4

Process
Inherent Cisplatin Resistance
Response to DNA-damage
DNA-damage
DNA Repair
Cell Cycle Checkpoint
Adaptive Cisplatin Resistance
Response to DNA Damage
Stimulus
DNA Repair
Double-strand Break Repair
Nucleotide-Excision Repair
Cell Cycle Checkpoint
DNA Replication

ATAD5, BRCC3, BLM, DCLRE1A, FANCB, FANCI, GEN1, RAD50, RAD54B, RIF1, SMG1, SLK,
BRCA2, CASP3, ESCO1, MNAT1, NBN, POLK, POLA1, POLQ, RCF1, RBBP8, SETX, SMC3,
SMC5, SMC6, TOP2A, TOPBP1, USP1, UACA
BRCC3, BLM, DCLRE1A, FANCB, FANCI, GEN1, RAD50, RAD54B, SMG1, SLK, BRCA2,
ESCO1, MNAT1, NBN, POLK, POLA1, POLQ, RCF1, RBBP8, SETX, SMC3, SMC5, SMC6,
TOP2A, TOPBP1, USP1
BRCC3, BLM, RAD50, RAD54B, BRCA2, NBN, POLA1, SETX
DCLRE1A, SLK, BRCA2, MNAT1, RFC1
BRCC3, BLM, TTK, CENPE, CENPF, NBN, RBBP8, TPR
XRN1, POLA1, TOPO2A, TOPO2B

an increased ability to recognise, process and repair ICLs,
which is associated with the increased cisplatin tolerance of
these cells (Figure 6c). This prolonged cell cycle mechanism
is likely to explain the longer time of xenograft tumour
formation observed in A2780cis cells (Figures 4c and d).
Taken together, these data identify these CSCs ability to selfheal as a potential clinical target, as discussed in detail later.
Low expression of CD10 is compatible with ovarian
cancer patient samples. The data described above suggest
that low CD10 expression may be associated with poor
outcome (response to platinum) in some ovarian cancer
patients. Although low marker expression is not clinically
ideal, it was important to demonstrate that high expression of
CD10 was not associated with poor outcome in ovarian
cancer patients. CD10 expression in ovarian cancer (endometrioid and serous) patient samples was assessed using
the online resource tool Kaplan–Meier Plotter, which facilitates filtered analysis across a large number of publically
available data sets. In each case, data are shown for p53 wild
type (‘p53wt’) or all p53 types (‘all p53’). Low CD10
expression was found to be associated with worse
progression-free survival (PFS, P = 0.00049), with a trend
towards worse overall survival (OS, P = 0.056) but only in
patients whose p53 status was wild type (n = 83, Figures 6d–
g). The ALDEFLOUR protocol used to detect ALDH expression in our studies is known to mark several members of the
ALDH family. Of the several ALDH proteins available on
Kaplan–Meier Plotter, low expression of only ALDH1A3 was
found to be associated with worse PFS (P = 0.021) again in
only p53wt patients (Figures 6h–k). We note that low
expression of ALDH1A3 is associated with (statistically
significant but modest hazard ratio (HR)) improved PFS
(P = 0.0092, HR = 1.22) and OS (P = 0.0033, HR = 1.23)
when all patients are considered. Further assessing the
biomarker utility of the gene signature, all inherent cisplatinresistance-specific genes listed in Table 1 were individually

3.2 × 10 − 4
2.8 × 10 − 3
4.9 × 10 − 2
1.2 × 10 − 8
1.1 × 10 − 8
5.5 × 10 − 4
3.8 × 10 − 2
5.2 × 10 − 2
2.3 × 10 − 3

assessed using Kaplan–Meier Plotter. Supporting the clinical
relevance of the inherent cisplatin-resistance mechanism
identified, the majority (~68%) of these genes were found to
be statistically significant predictors of PFS, 17 genes with
HRs of ⩾ 1.3 (TOPBP1, EYA4, USP1, UACA, TPR, SMC4,
SMC3, SLK, SKA3, RFC3, RFC1, PDS5B, PBRM1, KIF20B,
ITGB1, FANCL, CENPF; Supplementary Data 8). As a further
validation, we assessed CD10 expression in a tissue
microarray (TMA) consisting of 46 high-grade (serous)
ovarian cancer patients (demographics detailed in
Supplementary Data 8). Although strong CD10 expression
was observed in positive control tissue (Figure 6l) contained
in the TMA, the epithelium of all tumours was negative or
showed at most focal non-specific staining (Figure 6m). As
such, while further analysis and validation is required, low
CD10 expression is consistent with specific sets of ovarian
cancer patient samples.
Discussion
In this study, we used a single-cell analysis approach to build a
new ovCSC hierarchy model, which facilitated testing of the
respective chemoresistance of each CSC type. Our data
indicated that, in this model, chemoresistance is specific to
both CSC type and drug type. Historically, chemoresistance
has been thought of as a general property of CSCs. Our data
indicates that, within the tumour, different populations of CSC
can be responsible for resistance to specific chemotherapy
drugs. In concordance with this, we have found that only
ALDH+ (but not ALDH-) CSCs are cisplatin resistant in three
models of lung cancer.14 These are the first studies of their
kind and require examination in other malignancies. However,
these data have potential implications for clinical targeting of
CSCs, which are now discussed.
Our study has implications for our understanding of CSC
theory and hierarchy organisation. It is evident that CSCs can
be organised as a non-linear network where the apex CSC can
Cell Death and Disease
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be produced by a less potent progenitor and that progenitor
CSCs can produce one another. This indicates that the apex
CSC can be regenerated by a lower potency progenitor and
may thus be a less attractive clinical target in some types of
malignancy.3 It is also evident that a CSC hierarchy may
contain chemosensitive and chemoresistant components,
which are dramatically altered by chemotherapy treatment.
Pretreatment and posttreatment, CSCs can express multiple
specific chemoresistance mechanisms. These changes
persist after removal of cisplatin, suggesting that they are
hard-wired by chemotherapy. As we have discussed in our
recent review,8 this presents a clinical consideration where
CSC hierarchies can be dynamic rather than fixed targets,
which must be modelled to identify appropriate clinical targets.
Where appropriate clinical targets can be identified by
approaches such as those described herein, there is great
hope for the translation of CSC targeting to the clinic. To
facilitate clinical translation, it is important that the principles
identified herein are tested in other malignancies to identify
malignancy-specific CSC targets.
In terms of ovCSCs specifically, a previous consensus
model informed by the current literature indicates that ovarian
cancer is characterised by a hierarchical network of CSC
types.15 The authors highlight that the ‘XXX’ marker for the
‘XXX+?’/ALDH−/CD133−/CD44−/CD117− apex CSC must be
identified. The model we have identified is evidence for
CD10−/ALDH− CSCs (also CD133−/CD44−/CD117−,
Supplementary Data 1) as the consensus model apex CSC.
However, as our model contrasts the Burgos–Ojeda model by
placing a different cell (CD10+/ALDH+) at the apex of the
hierarchy, clearly more work is required to understand the full
disease. It is particularly important for ovarian cancer, which is
recognised as a collection of different diseases, that highly
specific analysis of CSCs associated with specific malignant
traits displayed by specific types of disease is undertaken.3
Finally, our data offer a clinical consideration where, in
future, it may be possible to exploit CSC analysis to identify
groups of patients that are likely to respond to specific
chemotherapy regimens, which has been highly successful
in breast cancer treatment.25–27 The data presented in this
study are evidence for the presence of a subdivision of ovarian
cancer that may respond better to paclitaxel than to cisplatin.
Together with our similar work in lung cancer,14 the data
presented herein support the hypothesis that CSC analysis
may facilitate future triaging of patients into specific chemotherapy response groups. It is important to follow this study
with a similar approach directed towards elucidation of the
relationship between CSC hierarchies and chemoresistance
in other cancer models.
Although low and high expression of BRCA1 is associated
with cisplatin sensitivity and resistance, respectively,19,20 our
highlighting of a link between high BRCA2 expression and
cisplatin resistance has rarely been described.21–23 Reactivation of BRCA2 via secondary mutations is linked to cisplatin
resistance due to restored DDR in inherited ovarian
cancer.22,23 Antisense targeting of BRCA2 in cancer cells
with functional HR has been shown to enhance cisplatin
response.24 Our results here suggest a potential for clinical
targeting of FA/BRCA2 pathway overexpression in specific
platinum-resistant patients. Selective targeting of an intact FA/
Cell Death and Disease

BRCA2 pathway is an emerging approach to cancer
therapy.25–28 Several FA pathway inhibitors have been
developed and shown to be successful in addressing cisplatin
resistance.29,30 Although more development is required, FA
targeting clearly represents a potential clinical strategy.
Together, our data support a hypothesis where a specific
drug may be appropriate for a specific patient group but
associated with some negative effects for another patient
group, a concept that has been demonstrated in breast cancer.
Targeting specific DDR mechanisms may offer hope for future
translation to the clinic. Finally, our data indicate an attractive
clinical approach, where, in specific patients, targeting of
CD10−/ALDH− CSCs at initial treatment may be sufficient to
compromise the development/progression of recurrent ovarian disease.
Materials and Methods
Cell culture and drug treatments. Cell lines (A2780/A2780cis) and
culturing are as previously described.13 Where stated, A2780cis cells were cultured
in the absence of cisplatin. Cisplatin (Hospira, Maidenhead, UK) was donated by the
Aseptic Compounding Unit, St. James’s Hospital, Dublin, Ireland. Paclitaxel powder
(Sigma, Wicklow, Ireland) was prepared in dimethyl sulphoxide (DMSO). For IC50
analysis, 5000 cells/well in a 96-well plate were treated with concentration ranges of
0.01–800 μM and 9 mg/ml sodium chloride (Cisplatin) and 0.0375–625 nM
(Paclitaxel), using vehicle controls of 1 mg/ml mannitol (Cisplatin) and DMSO
(Paclitaxel). After 48 h, cell viability was assessed using the Cell Counting Kit-8
(CCK-8, Sigma). IC50 values were calculated using GraphPad Prism (La Jolla, CA,
USA).
Histological and transcriptomic analysis of patient samples. A
TMA was prepared from a cohort composed of 46 patients with high-grade serous
carcinoma of tubal/ovarian origin. Cases were represented as triplicate cores and
39 cases contained at least 2 assessable cores. A list of the demographics for each
patient is available in Supplementary Data 8. Sections were cut at 4 μm intervals.
Germinal centres of tonsil were used as a positive control. CD10 (DAKO (Stockport,
UK) clone 56C5, code M7308) staining was carried on a Ventana BenchMark XT
(Tucson, AZ, USA) at a 1 : 40 dilution using CC2 antigen retrieval. Detection was
achieved using the Ventana Optiview Kit. An additional publically available data set
was interrogated using the online resource Kaplan–Meier Plotter (kmplot.com).
Statistical analysis. Statistical analysis was performed using GraphPad Prism
6. The unpaired Student’s t-test was used to compare two population means. A oneway ANOVA was carried to compare three or more population means. A P-value of
o0.05 was considered statistically significant. Data are represented as mean and
S.D. of n = 3. Kaplan–Meier analysis was used to calculate PFS and OS from the
TMA. Patient survival time was compared by the log-rank test. All significance
testing was two-sided, where a P-value ⩽ 0.05 was considered to be statistically
significant.
Additional methods. Validation of CSCs, via xenograft and SCAD assay, and
flow cytometric analysis are described in Supplementary Data 1.
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